WEST virginia Legislature
2017 regular session
By
[
to the Committee on Prevention and Treatment of Substance Abuse then Health
and Human Resources then the Judiciary.
A BILL to amend the Code
of West Virginia, 1931, as amended, by adding thereto a new article designated §16-52-1,
§16-52-2, §16-52-3 and §16-52-4; and to amend and reenact §60A-2-204 of said code, all relating to authorizing the
medical use of pharmaceutical cannabis to treat certain medical conditions for
which no other satisfactory alternative treatment option exists.
Be it enacted by the
Legislature of West Virginia:
That the Code of West
Virginia, 1931, as amended, be amended by adding thereto a new article,
designated §16-52-1, §16-52-2, §16-52-3 and §16-52-4; and that §60A-2-204 of said code, be amended and reenacted, all to
read as follows:
chapter 16. public health.
ARTICLE 52. COMPASSIONATE
USE OF LOW DOSE THC.
§16-52-1. Legislative
findings.
The purpose of this article is to
legalize the use of cannabis-based pharmaceutical products that in the medical
judgment of an attending physician, is an appropriate medical treatment for a
person diagnosed with cancer or a disease, disorder or condition in which use
of the cannabis based pharmaceutical product alleviates symptoms such as
seizures, severe and persistent muscle spasm, and no other satisfactory
alternative treatment option exists for the patient.
§16-52-2.
Definitions.
As used
in this article, the term:
(a) “Dispensing
organization” means an organization approved by the department to dispense
low-THC cannabis pursuant to this article;
(b) “Low-THC
cannabis” means a plant of the genus Cannabis, the dried flowers of which
contain 0.8 percent or less of tetrahydrocannabinol and more than ten percent
of cannabidiol weight for weight; the seeds thereof; the resin extracted from
any part of such plant; or any compound, manufacture, salt, derivative,
mixture, or preparation of such plant or its seeds or resin that is dispensed
only from a dispensing organization;
(c) “Medical
use” means administration of the ordered amount of low-THC cannabis. The term
does not include the possession, use, or administration by smoking. The term
also does not include the transfer of low-THC cannabis to a person other than
the patient for whom it was ordered or the patient’s legal representative on
behalf of the qualified patient;
(d) “Smoking”
means burning or igniting a substance and inhaling the smoke. Smoking does not
include the use of a vaporizer.
§16-52-3. Physician
prescription authority.
A physician licensed
under article three or fourteen, chapter thirty of this code who has examined
and is treating a patient suffering from cancer or a physical medical condition
that chronically produces symptoms such as seizures or severe and persistent
muscle spasms may order for the patient’s medical use low-THC cannabis to treat
such disease, disorder, or condition or to alleviate symptoms of such disease,
disorder, or condition, if no other satisfactory alternative treatment options
exist for that patient and all of the following conditions apply:
(1) The
patient is a permanent resident of this state;
(2) The
physician determines that the risks of ordering low-THC cannabis are reasonable
in light of the potential benefit for that patient. If a patient is younger
than eighteen years of age, a second physician must concur with this
determination, and such determination must be documented in the patient’s
medical record;
(3) The
physician maintains a patient treatment plan that includes the dose, route of
administration, planned duration, and monitoring of the patient’s symptoms and
other indicators of tolerance or reaction to the low-THC cannabis;
(4) The
physician obtains the voluntary informed consent of the patient or the patient’s
legal guardian to treatment with low-THC cannabis after sufficiently explaining
the current state of knowledge in the medical community of the effectiveness of
treatment of the patient’s condition with low-THC cannabis, the medically
acceptable alternatives, and the potential risks and side effects; and
(5) The
physician complies with any additional conditions or directives that are
established by his or her licensing board or the Secretary of the Department of
Health and Human Resources.
§16-52-4. Duties of the Secretary.
The Secretary
of the Department of Health and Human Resources shall propose rules for
legislative approval in accordance with the provisions of article three,
chapter twenty-nine-a of this code, necessary to effectuate the provisions of
this article, including but not limited to:
(1)
Establish any limitations, conditions or requirements on the dispensing of
low-THC cannabis necessary to protect public health and prevent diversion of it
for any unlawful purpose; and
(2) Authorizing and
regulating dispensing organizations to ensure reasonable statewide
accessibility and availability as necessary for patients that have been
prescribed low-THC cannabis pursuant to this article.
chapter 60a. uniform
controlled substances act.
article 2. standards and
schedules.
§60A-2-204. Schedule I.
(a) Schedule I shall
consist of the drugs and other substances, by whatever official name, common or
usual name, chemical name, or brand name designated, listed in this section.
(b) Opiates. Unless
specifically excepted or unless listed in another schedule, any of the
following opiates, including their isomers, esters, ethers, salts and salts of
isomers, esters and ethers, whenever the existence of such isomers, esters,
ethers and salts is possible within the specific chemical designation (for
purposes of subdivision (34) of this subsection only, the term isomer includes
the optical and geometric isomers):
(1) Acetyl-alpha-methylfentanyl
(N-[1-(1-methyl-2-phenethyl) -4-piperidinyl]--phenylacetamide);
(2) Acetylmethadol;
(3) Allylprodine;
(4) Alphacetylmethadol
(except levoalphacetylmethadol also known as levo-alpha-acetylmethadol,
levomethadyl acetate, or LAAM);
(5) Alphameprodine;
(6) Alphamethadol;
(7)Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl)
ethyl-4-piperidyl] propionanilide; 1-(1-methyl-2-phenylethyl)-4-(B
propanilido) piperidine);
(8) Alpha-methylthiofentanyl
(N-[1-methyl-2-(2-thienyl) ethyl- 4-piperidinyl]--phenylpropanamide);
(9) Benzethidine;
(10) Betacetylmethadol;
(11)
Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl) -4- piperidinyl]-N-phenylpropanamide);
(12)
Beta-hydroxy-3-methylfentanyl (other name: N-[1-(2- hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-N-phenylpropanamide);
(13) Betameprodine;
(14) Betamethadol;
(15) Betaprodine;
(16) Clonitazene;
(17) Dextromoramide;
(18) Diampromide;
(19) Diethylthiambutene;
(20) Difenoxin;
(21) Dimenoxadol;
(22) Dimepheptanol;
(23) Dimethylthiambutene;
(24) Dioxaphetyl butyrate;
(25) Dipipanone;
(26)
Ethylmethylthiambutene;
(27) Etonitazene;
(28) Etoxeridine;
(29) Furethidine;
(30) Hydroxypethidine;
(31) Ketobemidone;
(32) Levomoramide;
(33) Levophenacylmorphan;
(34) 3-Methylfentanyl
(N-[3-methyl-1-(2-phenylethyl)-4- piperidyl]-N-phenylpropanamide);
(35)
3-methylthiofentanyl (N-[3-methyl-1-(2-thienyl) ethyl-4- piperidinyl]--phenylpropanamide);
(36) Morpheridine;
(37) MPPP
(1-methyl-4-phenyl-4-propionoxypiperidine);
(38) Noracymethadol;
(39) Norlevorphanol;
(40) Normethadone;
(41) Norpipanone;
(42)
Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2- phenethyl)-4-piperidinyl]
propanamide);
(43) PEPAP(1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine);
(44) Phenadoxone;
(45) Phenampromide;
(46) Phenomorphan;
(47) Phenoperidine;
(48) Piritramide;
(49) Proheptazine;
(50) Properidine;
(51) Propiram;
(52) Racemoramide;
(53) Thiofentanyl
(N-phenyl-N-[1-(2-thienyl)ethyl-4- piperidinyl]-propanamide);
(54) Tilidine;
(55) Trimeperidine.
(c) Opium derivatives.
-- Unless specifically excepted or unless listed in another schedule, any of
the following opium immediate derivatives, its salts, isomers and salts of
isomers whenever the existence of such salts, isomers and salts of isomers is possible
within the specific chemical designation:
(1) Acetorphine;
(2) Acetyldihydrocodeine;
(3) Benzylmorphine;
(4) Codeine methylbromide;
(5) Codeine-N-Oxide;
(6) Cyprenorphine;
(7) Desomorphine;
(8) Dihydromorphine;
(9) Drotebanol;
(10) Etorphine (except HCl
Salt);
(11) Heroin;
(12) Hydromorphinol;
(13) Methyldesorphine;
(14) Methyldihydromorphine;
(15) Morphine
methylbromide;
(16) Morphine
methylsulfonate;
(17) Morphine-N-Oxide;
(18) Myrophine;
(19) Nicocodeine;
(20) Nicomorphine;
(21) Normorphine;
(22) Pholcodine;
(23) Thebacon.
(d) Hallucinogenic
substances. -- Unless specifically excepted or unless listed in another
schedule, any material, compound, mixture or preparation, which contains any
quantity of the following hallucinogenic substances, or which contains any of
its salts, isomers and salts of isomers, whenever the existence of such salts,
isomers, and salts of isomers is possible within the specific chemical
designation (for purposes of this subsection only, the term "isomer" includes
the optical, position and geometric isomers):
(1) Alpha-ethyltryptamine; some trade or other names:
etryptamine; Monase; alpha-ethy-1H-indole-3-ethanamine; 3-(2- aminobutyl)
indole; alpha-ET; and AET;
(2) 4-bromo-2,
5-dimethoxy-amphetamine; some trade or other names: 4-bromo-2,5-dimethoxy-alpha-methylphenethylamine;
4-bromo- 2,5-DMA;
(3)
4-Bromo-2,5-dimethoxyphenethylamine; some trade or other names: 2-(4-bromo-2,5-dimethoxyphenyl)-1-aminoethane;
alpha- desmethyl DOB; 2C-B, Nexus;
(4)(A) N-(2-Methoxybenzyl)-4-bromo-2,
5-dimethoxyphenethylamine. The substance has the acronym 25B-NBOMe.
(B)
2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine (25C-NBOMe).
(C)
2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine (25I-NBOMe)
(5) 2,5-dimethoxyamphetamine;
some trade or other names: 2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA;
(6)
2,5-dimethoxy-4-ethylamphet-amine; some trade or other names: DOET;
(7)
2,5-dimethoxy-4-(n)-propylthiophenethylamine (other name: 2C-T-7);
(8) 4-methoxyamphetamine;
some trade or other names: 4-methoxy-alpha-methylphenethylamine;
paramethoxyamphetamine; PMA;
(9) 5-methoxy-3,
4-methylenedioxy-amphetamine;
(10)
4-methyl-2,5-dimethoxy-amphetamine; some trade and other names:
4-methyl-2,5-dimethoxy-alpha-methylphenethylamine; "DOM"; and "STP";
(11) 3,4-methylenedioxy
amphetamine;
(12)
3,4-methylenedioxymethamphetamine (MDMA);
(13)
3,4-methylenedioxy-N-ethylamphetamine (also known as B
ethyl-alpha-methyl-3,4 (methylenedioxy) phenethylamine, N-ethyl MDA, MDE, MDEA);
(14)
N-hydroxy-3,4-methylenedioxyamphetamine (also known as B hydroxy-alpha-methyl-3,4
(methylenedioxy) phenethylamine, and B hydroxy MDA);
(15) 3,4,5-trimethoxy
amphetamine;
(15) (16)
5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT);
(17) Alpha-methyltryptamine
(other name: AMT);
(18) Bufotenine; some trade
and other names: 3-(beta-Dimethylaminoethyl)-5-hydroxyindole;3-(2-dimethylaminoethyl)
-5-indolol; N, N-dimethylserotonin; 5-hydroxy-N,N- dimethyltryptamine; mappine;
(19) Diethyltryptamine;
sometrade and other names: N, N-Diethyltryptamine; DET;
(20) Dimethyltryptamine;
some trade or other names: DMT;
(21)
5-Methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT);
(22) Ibogaine; some trade
and other names: 7-Ethyl-6, 6 Beta, 7, 8, 9, 10, 12, 13-octahydro-2-methoxy-6,
9-methano-5H- pyrido [1’, 2’: 1, 2] azepino [5,4-b] indole; Tabernanthe iboga;
(23) Lysergic acid
diethylamide;
(24) Marihuana;
(25) Mescaline;
(26) Parahexyl-7374; some
trade or other names: 3-Hexyl -1-hydroxy-7, 8, 9, 10-tetrahydro-6, 6,
9-trimethyl-6H-dibenzo [b,d] pyran; Synhexyl;
(27) Peyote; meaning all
parts of the plant presently classified botanically as Lophophora williamsii
Lemaire, whether growing or not, the seeds thereof, any extract from any part
of such plant, and every compound, manufacture, salts, immediate derivative,
mixture or preparation of such plant, its seeds or extracts;
(28) N-ethyl-3-piperidyl
benzilate;
(29) N-methyl-3-piperidyl
benzilate;
(30) Psilocybin;
(31) Psilocyn;
(32) Tetrahydrocannabinols;
synthetic equivalents of the substances contained in the plant, or in the
resinous extractives of Cannabis, sp. and/or synthetic substances, immediate
derivatives and their isomers with similar chemical structure and
pharmacological activity such as the following:
delta-1 Cis or trans
tetrahydrocannabinol, and their optical isomers;
delta-6 Cis or trans
tetrahydrocannabinol, and their optical isomers;
delta-3,4 Cis or trans
tetrahydrocannabinol, and its optical isomers;
(Since nomenclature of
these substances is not internationally standardized, compounds of these
structures, regardless of numerical designation of atomic positions covered.): Provided, That low-THC
cannabis, as defined, distributed, and regulated pursuant to article fifty-two,
chapter sixteen of this code, is not considered a schedule 1 drug pursuant to
this section.
(33) Ethylamine analog of
phencyclidine; some trade or other names: N-ethyl-1-phenylcyclohexylamine,
(1-phenylcyclohexyl) ethylamine, N-(1-phenylcyclohexyl) ethylamine, cyclohexamine,
PCE;
(34) Pyrrolidine analog of
phencyclidine; some trade or other names: 1-(1-phenylcyclohexyl)-pyrrolidine,
PCPy, PHP;
(35) Thiophene analog of
phencyclidine; some trade or other names:
1-[1-(2-thienyl)-cyclohexyl]-piperidine, 2-thienylanalog of phencyclidine;
TPCP, TCP;
(36)
1[1-(2-thienyl)cyclohexyl]pyrroldine; some other names: TCPy.
(37) 4-methylmethcathinone
(Mephedrone);
(38)
3,4-methylenedioxypyrovalerone (MDPV);
(39)
2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E);
(40) 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine
(2C-D)
(41)
2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C)
(42)
2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I)
(43)
2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2)
(44)
2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4)
(45)
2-(2,5-Dimethoxyphenyl)ethanamine (2C-H)
(46)
2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N)
(47) 2-(2,5-Dimethoxy-
4-(n)-propylphenyl)ethanamine
(2C-P)
(48)
3,4-Methylenedioxy-N-methylcathinone (Methylone)
(49)(2,5-dimethoxy-4-(n)-propyltghiophenethylamine
(2C-T-7, itsoptical isomers, salts and salts of isomers
(50)
5-methoxy-N,N-dimethyltryptamine some trade or other names:
5-methoxy-3-[2-(dimethylamino)ethyl]indole; 5-MeO-DMT(5-MeO-DMT)
(51) Alpha-methyltryptamine
(other name: AMT)
(52)
5-methoxy-N,N-diisopropyltryptamine (other name: 5-MeO-DIPT)
(53) Synthetic Cannabinoids
as follows:
(A)
2-[(1R,3S)-3-hydroxycyclohexyl]-5- (2-methyloctan-2-yl)phenol) {also known as
CP 47,497 and homologues};
(B) rel-2-[(1S,3R)-3-hydroxycyclohexyl]
-5-(2-methylnonan-2-yl)phenol {also known as CP 47,497-C8 homolog};
(C) [(6aR)-9-(hydroxymethyl)-6,
6-dimethyl-3-(2-methyloctan-2-yl)-6a, 7,10,10a-tetrahydrobenzo[c]chromen-1-ol)]
{also known as HU-210};
(D) (dexanabinol);
(6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo
l[c]chromen-1-ol) {also
known as HU-211};
(E)
1-Pentyl-3-(1-naphthoyl)indole {also known as JWH-018};
(F)
1-Butyl-3-(1-naphthoyl)indole {also known as JWH-073};
(G) (2-methyl-1-propyl-1H-indol-3-yl)-1-napthalenyl-methanone
{also known as JWH-015};
(H)
(1-hexyl-1H-indol-3-yl)-1-naphthalenyl-methanone {also known as JWH-019};
(I) [1-[2-(4-morpholinyl)
ethyl] -1H-indol-3-yl]-1-naphthalenyl-methanone {also known as JWH-200};
(J) 1-(1-pentyl-1H-indol-3-yl)-2-(3-hydroxyphenyl)-ethanone
{also known as JWH-250};
(K)
2-((1S,2S,5S)-5-hydroxy-2- (3-hydroxtpropyl)cyclohexyl)
-5-(2-methyloctan-2-yl)phenol {also known as CP 55,940};
(L)
(4-methyl-1-naphthalenyl) (1-pentyl-1H-indol-3-yl) -methanone {also known as
JWH-
122};
(M)
(4-methyl-1-naphthalenyl) (1-pentyl-1H-indol-3-yl) -methanone {also known as
JWH-
398;
(N)
(4-methoxyphenyl)(1-pentyl-1H-indol-3-yl)methanone {also known as RCS-4};
(O)
1-(1-(2-cyclohexylethyl) -1H-indol-3-yl) -2-(2-methoxyphenyl) ethanone {also
known as RCS-8};
(P)
1-pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH-081);
(Q)
1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM2201); and
(R)
1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM694).
(54) Synthetic cannabinoids
or any material, compound, mixture or preparation which contains any quantity
of the following substances, including their analogues, congeners, homologues,
isomers, salts and salts of analogues, congeners, homologues and isomers, as
follows:
(A) CP 47,497 AND
homologues, 2-[(1R,3S)-3-Hydroxycyclohexyl]-5-(2-methyloctan-2-
YL)phenol);
(B) HU-210, [(6AR,10AR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-Methyloctan-2-YL)-6A,7,10,
10A-tetrahydrobenzo[C] chromen-1-OL)];
(C) HU-211, (dexanabinol,
(6AS,10AS)-9-(hydroxymethyl)-6,6-Dimethyl-3-(2-methyloctan-2-YL)-6A,7,10,10atetrahydrobenzo[
C]chromen-1-OL);
(D) JWH-018,
1-pentyl-3-(1-naphthoyl)indole;
(E) JWH-019,
1-hexyl-3-(1-naphthoyl)indole;
(F) JWH-073,
1-butyl-3-(1-naphthoyl)indole;
(G) JWH-200,
(1-(2-morpholin-4-ylethyl)indol-3-yl)- Naphthalen-1-ylmethanone;
(H) JWH-250,
1-pentyl-3-(2-methoxyphenylacetyl)indole.]
(55) Synthetic cannabinoids
including any material, compound, mixture or preparation that is not listed as
a controlled substance in Schedule I through V, is not a federal Food and Drug
Administration approved drug or used within legitimate and approved medical
research and which contains any quantity of the following substances, their
salts, isomers, whether optical positional or geometric, analogues, homologues and
salts of isomers, analogues and homologues, unless specifically exempted,
whenever the existence of these salts, isomers, analogues, homologues and salts
of isomers, analogues and homologues if possible within the specific chemical
designation:
(A) Tetrahydrocannabinols
meaning tetrahydrocannabinols which are naturally contained in a plant of the
genus cannabis as well as synthetic equivalents of the substances contained in
the plant or in the resinous extractives of cannabis or synthetic substances, derivatives
and their isomers with analogous chemical structure and or pharmacological
activity such as the following:
(i) DELTA-1 CIS OR trans
tetrahydrocannabinol and their Optical isomers.
(ii) DELTA-6 CIS OR trans
tetrahydrocannabinol and their optical isomers.
(iii) DELTA-3,4 CIS or
their trans tetrahydrocannabinol and their optical isomers.
(B) Naphthoylindoles or any
compound containing a 3-(-1- Napthoyl) indole structure with substitution at
the nitrogen atom of the indole ring whether or not further substituted in the
indole ring to any extent and whether or not substituted in the naphthyl ring
to any extent. This shall include the following:
(i) JWH 015;
(ii) JWH 018;
(iii) JWH 019;
(iv) JWH 073;
(v) JWH 081;
(vi) JWH 122;
(vii) JWH 200;
(viii) JWH 210;
(ix) JWH 398;
(x) AM 2201;
(xi) WIN 55,212.
(56) Naphylmethylindoles or
any compound containing a 1hindol-3-yl-(1-naphthyl) methane structure with a
substition at the nitrogen atom of the indole ring whether or not further
substituted in the indole ring to any extent and whether or not substituted in
the naphthyl ring to any extent. This shall include, but not be limited to, JWH
175 and JWH 184.
(57) Naphthoylpyrroles or
any compound containing a 3-(1- Naphthoyl) pyrrole structure with substitution
at the nitrogen atom of the pyrrole ring whether or not further substituted in
the pyrrole ring to any extent and whether or not substituted in the naphthyl
ring to any extent. This shall include, but not be limited to, JWH 147 and JWH
307.
(58) Naphthylmethylindenes
or any compound containing a Naphthylideneindene structure with substitution at
the 3- Position of the indene ring whether or not further substituted in the
indene ring to any extent and whether or not substituted in the naphthyl ring
to any extent. This shall include, but not be limited to, JWH 176.
(59) Phenylacetylindoles or
any compound containing a 3- Phenylacetylindole structure with substitution at
the nitrogen atom of the indole ring whether or not further substituted in the
indole ring to any extent and whether or not substituted in the phenyl ring to
any extent. This shall include the following:
(A) RCS-8, SR-18 OR BTM-8;
(B) JWH 250;
(C) JWH 203;
(D) JWH 251;
(E) JWH 302.
(60) Cyclohexylphenols or
any compound containing a 2-(3- hydroxycyclohexyl) phenol structure with a
substitution at the 5-position of the phenolic ring whether or not substituted
in the cyclohexyl ring to any extent. This shall include the following:
(A) CP 47,497 and its
homologues and analogs;
(B) Cannabicyclohexanol;
(C) CP 55,940.
(61) Benzoylindoles or any
compound containing a 3-(benzoyl) indole structure with substitution at the
nitrogren atom of the indole ring whether or not further substituted in the
indole ring to any extent and whether or not substituted in the phenyl ring to
any extent. This shall include the following:
(A) AM 694;
(B) Pravadoline WIN 48,098;
(C) RCS 4;
(D) AM 679.
(62) [2,3-dihydro-5
methyl-3-(4-morpholinylmethyl)pyrrolo [1,2,3-DE]-1, 4-benzoxazin-6-YL]-1-napthalenymethanone.
This shall include WIN 55,212-2.
(63) Dibenzopyrans or any
compound containing a 11-hydroxydelta 8-tetrahydrocannabinol structure with
substitution on the 3-pentyl group. This shall include HU-210, HU-211, JWH 051
and JWH 133.
(64) Adamantoylindoles or
any compound containing a 3-(-1- Adamantoyl) indole structure with substitution
at the nitrogen atom of the indole ring whether or not further substituted in
the adamantoyl ring system to any extent. This shall include AM1248.
(65)
Tetramethylcyclopropylindoles or any compound containing A 3-tetramethylcyclopropylindole
structure with substitution at the nitrogen atom of the indole ring whether or
not further substituted in the indole ring to any extent and whether or not
substituted in the tetramethylcyclopropyl ring to any extent. This shall
include UR-144 and XLR-11.
(66)
N-(1-Adamantyl)-1-pentyl-1h-indazole-3-carboxamide. This shall include AKB48.
(67) Any other synthetic
chemical compound that is a Cannabinoid receptor type 1 agonist as demonstrated
by binding studies and functional assays that is not listed in Schedules II,
III, IV and V, not federal Food and Drug Administration approved drug or used
within legitimate, approved medical research. Since nomenclature of these
substances is not internationally standardized, any immediate precursor or
immediate derivative of these substances shall be covered.
(68) Tryptamines:
(A) 5- methoxy- N-
methyl-N-isopropyltryptamine (5-MeO-MiPT)
(B)
4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT)
(C)
4-hydroxy-N-methyl-N-isopropyltryptamine (4-HO-MiPT)
(D)
4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET)
(E)
4-acetoxy-N,N-diisopropyltryptamine (4-AcO-DiPT)
(F)
5-methoxy-α-methyltryptamine (5-MeO-AMT)
(G)
4-methoxy-N,N-Dimethyltryptamine (4-MeO-DMT)
(H) 4-hydroxy
Diethyltryptamine (4-HO-DET)
(I) 5- methoxy- N,N-
diallyltryptamine (5-MeO-DALT)
(J)
4-acetoxy-N,N-Dimethyltryptamine (4-AcO DMT)
(K) 4-hydroxy
Diethyltryptamine (4-HO-DET)
(e) Depressants. --
Unless specifically excepted or unless listed in another schedule, any material,
compound, mixture, or preparation which contains any quantity of the following
substances having a depressant effect on the central nervous system, including
its salts, isomers and salts of isomers whenever the existence of such salts,
isomers and salts of isomers is possible within the specific chemical
designation:
(1) Mecloqualone;
(2) Methaqualone.
(f) Stimulants. --
Unless specifically excepted or unless listed in another schedule, any
material, compound, mixture, or preparation which contains any quantity of the
following substances having a stimulant effect on the central nervous system,
including its salts, isomers and salts of isomers:
(1) Aminorex; some other
names: aminoxaphen; 2-amino-5- phenyl-2-oxazoline; or 4,5-dihydro-5-phenyl-2-oxazolamine;
(2) Cathinone; some trade
or other names: 2-amino-1-phenyl-1- propanone, alpha-aminopropiophenone,
2-aminopropiophenone and norephedrone;
(3) Fenethylline;
(4) Methcathinone, its
immediate precursors and immediate derivatives, its salts, optical isomers and
salts of optical isomers; some other names: (2-(methylamino)-propiophenone;
alpha-(methylamino)propiophenone; 2-(methylamino)-1-phenylpropan-1- one; alpha---methylaminopropiophenone;
monomethylpropion; 3,4-methylenedioxypyrovalerone and/or mephedrone;3,4-methylenedioxypyrovalerone
(MPVD); ephedrone; N-methylcathinone; methylcathinone; AL-464; AL-422; AL- 463
and UR1432;
(5) (+-)
cis-4-methylaminorex; ((+-)cis-4,5-dihydro-4-methyl- 5-phenyl-2-oxazolamine);
(6) N-ethylamphetamine;
(7) N,N-dimethylamphetemine;
also known as N,N-alpha- trimethyl-benzeneethanamine;
N,N-alpha-trimethylphenethylamine.
(8)
Alpha-pyrrolidinopentiophenone, also known as alpha-PVP, optical isomers, salts
and salts of isomers.
(9) Substituted
amphetamines:
(A) 2-Fluoroamphetamine
(B) 3-Fluoroamphetamine
(C) 4-Fluoroamphetamine
(D) 2-chloroamphetamine
(E) 3-chloroamphetamine
(F) 4-chloroamphetamine
(G) 2-Fluoromethamphetamine
(H) 3-Fluoromethamphetamine
(I) 4-Fluoromethamphetamine
(J) 4-chloromethamphetamine
(g) Temporary listing of substances
subject to emergency scheduling. Any material, compound, mixture or preparation
which contains any quantity of the following substances:
(1)
N-[1-benzyl-4-piperidyl]-N-phenylpropanamide (benzylfentanyl), its optical
isomers, salts, and salts of isomers.
(2)N-[1-(2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide
(thenylfentanyl), its optical isomers, salts and salts of isomers.
(3) N-benzylpiperazine,
also known as BZP.
(h) The following
controlled substances are included in Schedule I:
(1) Synthetic Cathinones or
any compound, except bupropion or compounds listed under a different schedule,
or compounds used within legitimate and approved medical research, structurally
derived from 2- Aminopropan-1-one by substitution at the 1-position with Monocyclic
or fused polycyclic ring systems, whether or not the compound is further
modified in any of the following ways:
(A) By substitution in the
ring system to any extent with Alkyl, alkylenedioxy, alkoxy, haloalkyl,
hydroxyl or halide Substituents whether or not further substituted in the ring
system by one or more other univalent substituents.
(B) By substitution at the
3-position with an acyclic alkyl substituent.
(C) By substitution at the
2-amino nitrogen atom with alkyl, dialkyl, benzyl or methoxybenzyl groups.
(D) By inclusion of the
2-amino nitrogen atom in a cyclic structure.
(2) Any other synthetic
chemical compound that is a Cannabinoid receptor type 1 agonist as demonstrated
by binding studies and functional assays that is not listed in Schedules II,
III, IV and V, not federal Food and Drug Administration approved drug or used
within legitimate, approved medical research.
NOTE: The purpose of this bill is
to authorize the medical use of pharmaceutical cannabis to treat certain
medical conditions for which no other satisfactory alternative treatment option
exists.
Strike-throughs indicate language
that would be stricken from a heading or the present law and underscoring
indicates new language that would be added.